JP6134783B2 - 外傷性脳損傷の処置のため、および神経因性細胞の移動の調節のための方法および組成物 - Google Patents

外傷性脳損傷の処置のため、および神経因性細胞の移動の調節のための方法および組成物 Download PDF

Info

Publication number
JP6134783B2
JP6134783B2 JP2015512636A JP2015512636A JP6134783B2 JP 6134783 B2 JP6134783 B2 JP 6134783B2 JP 2015512636 A JP2015512636 A JP 2015512636A JP 2015512636 A JP2015512636 A JP 2015512636A JP 6134783 B2 JP6134783 B2 JP 6134783B2
Authority
JP
Japan
Prior art keywords
cells
cell
tbi
brain injury
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015512636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517520A5 (enExample
JP2015517520A (ja
Inventor
シーザー ブイ． ボーロンガン，
シーザー ブイ． ボーロンガン，
ケイシー シー． ケース，
ケイシー シー． ケース，
Original Assignee
サンバイオ，インコーポレイティド
ユニヴァーシティ オブ サウス フロリダ
ユニヴァーシティ オブ サウス フロリダ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンバイオ，インコーポレイティド, ユニヴァーシティ オブ サウス フロリダ, ユニヴァーシティ オブ サウス フロリダ filed Critical サンバイオ，インコーポレイティド
Publication of JP2015517520A publication Critical patent/JP2015517520A/ja
Publication of JP2015517520A5 publication Critical patent/JP2015517520A5/ja
Application granted granted Critical
Publication of JP6134783B2 publication Critical patent/JP6134783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015512636A 2012-05-16 2013-03-13 外傷性脳損傷の処置のため、および神経因性細胞の移動の調節のための方法および組成物 Active JP6134783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647893P 2012-05-16 2012-05-16
US61/647,893 2012-05-16
PCT/US2013/030895 WO2013172944A1 (en) 2012-05-16 2013-03-13 Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016184086A Division JP2016220694A (ja) 2012-05-16 2016-09-21 外傷性脳損傷の処置のため、および神経因性細胞の移動の調節のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2015517520A JP2015517520A (ja) 2015-06-22
JP2015517520A5 JP2015517520A5 (enExample) 2015-10-29
JP6134783B2 true JP6134783B2 (ja) 2017-05-24

Family

ID=48040424

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015512636A Active JP6134783B2 (ja) 2012-05-16 2013-03-13 外傷性脳損傷の処置のため、および神経因性細胞の移動の調節のための方法および組成物
JP2016184086A Pending JP2016220694A (ja) 2012-05-16 2016-09-21 外傷性脳損傷の処置のため、および神経因性細胞の移動の調節のための方法および組成物
JP2018082259A Pending JP2018111733A (ja) 2012-05-16 2018-04-23 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物
JP2021038508A Pending JP2021098738A (ja) 2012-05-16 2021-03-10 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物
JP2023078339A Pending JP2023099213A (ja) 2012-05-16 2023-05-11 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物
JP2025030492A Pending JP2025098021A (ja) 2012-05-16 2025-02-27 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2016184086A Pending JP2016220694A (ja) 2012-05-16 2016-09-21 外傷性脳損傷の処置のため、および神経因性細胞の移動の調節のための方法および組成物
JP2018082259A Pending JP2018111733A (ja) 2012-05-16 2018-04-23 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物
JP2021038508A Pending JP2021098738A (ja) 2012-05-16 2021-03-10 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物
JP2023078339A Pending JP2023099213A (ja) 2012-05-16 2023-05-11 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物
JP2025030492A Pending JP2025098021A (ja) 2012-05-16 2025-02-27 外傷性脳損傷後のバイオブリッジ形成時に発現する組成物

Country Status (7)

Country Link
US (4) US9828593B2 (enExample)
EP (1) EP2849766B1 (enExample)
JP (6) JP6134783B2 (enExample)
CN (3) CN109718250B (enExample)
AU (2) AU2013263417B2 (enExample)
CA (1) CA2872188C (enExample)
WO (1) WO2013172944A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109718250B (zh) 2012-05-16 2022-08-30 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
EP2906293B1 (en) 2012-10-09 2018-12-12 SanBio, Inc. Methods and compositions for treatment of retinal degeneration
WO2015120388A1 (en) * 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CA2981523A1 (en) * 2015-04-01 2016-10-06 Sanbio, Inc. Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms
KR101986366B1 (ko) * 2016-02-26 2019-06-07 주식회사 이노퓨틱스 Ｎｕｒｒ１과 Ｆｏｘａ２의 교질세포 기능 조절에 의한 염증성 신경질환 치료
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
WO2018125829A1 (en) 2016-12-28 2018-07-05 Sanbio, Inc. Cell delivery system and methods of operation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
JP3886346B2 (ja) 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
CA2475288C (en) 2002-02-06 2014-09-02 Sanbio, Inc. Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
EP1635805A4 (en) 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
KR20130062359A (ko) 2004-04-12 2013-06-12 산바이오 인코포레이티드 뉴런의 전구 세포 특징들을 나타내는 세포
EP1855700B1 (en) 2005-03-07 2013-10-30 SanBio, Inc. Use of neuronal precursor cells for treatment of central nervous system lesions
CN101008033A (zh) * 2006-01-27 2007-08-01 陈云 功能性中枢神经损伤诊断检测用基因芯片及其制造方法
WO2008102460A1 (en) 2007-02-23 2008-08-28 Sanbio Inc. Transplantation of bone marrow stromal cell-induced neural stem cells for promoting fuctional recovery after spinal cord injury
WO2009023251A1 (en) * 2007-08-15 2009-02-19 Sanbio, Inc. Methods and compositions for treating neural degeneration
ES2787513T3 (es) 2007-12-03 2020-10-16 Sanbio Inc Métodos y composiciones para modular la diferenciación de células pluripotenciales
US10702554B2 (en) 2007-12-03 2020-07-07 Sanbio, Inc. Extracellular matrix from pluripotent cells
PL2274430T3 (pl) 2008-04-30 2017-09-29 Sanbio Inc Komórki regenerujące nerwy ze zmianami w metylacji DNA
WO2012154344A1 (en) 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US20120263681A1 (en) 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer
JP6306506B2 (ja) 2011-08-19 2018-04-04 サンバイオ，インコーポレイティド 神経原生及びグリア原生因子及びそれらについてのアッセイ
JP6023218B2 (ja) 2012-01-27 2016-11-09 サンバイオ，インコーポレイティド 血管新生及び血管発生を調節するための方法及び組成物
CN109718250B (zh) * 2012-05-16 2022-08-30 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Also Published As

Publication number Publication date
CN115381855A (zh) 2022-11-25
AU2016204910B2 (en) 2017-07-20
JP2015517520A (ja) 2015-06-22
CA2872188C (en) 2018-08-14
EP2849766A1 (en) 2015-03-25
JP2025098021A (ja) 2025-07-01
AU2013263417B2 (en) 2016-05-26
WO2013172944A1 (en) 2013-11-21
US20190185839A1 (en) 2019-06-20
US20200354709A1 (en) 2020-11-12
CN104519891A (zh) 2015-04-15
CN104519891B (zh) 2019-03-22
AU2013263417A1 (en) 2014-11-20
US20140186316A1 (en) 2014-07-03
US10626389B2 (en) 2020-04-21
CN109718250A (zh) 2019-05-07
CN109718250B (zh) 2022-08-30
US20150197741A1 (en) 2015-07-16
JP2016220694A (ja) 2016-12-28
JP2021098738A (ja) 2021-07-01
JP2018111733A (ja) 2018-07-19
EP2849766B1 (en) 2019-03-06
US9828593B2 (en) 2017-11-28
CA2872188A1 (en) 2013-11-21
AU2016204910A1 (en) 2016-08-04
HK1206631A1 (en) 2016-01-15
JP2023099213A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
US10626389B2 (en) Methods and compositions for modulation of migration of neurogenic cells
US20210228639A1 (en) Method of treating the effects of stroke
JP2018511599A (ja) 細胞増殖の刺激のための方法及び組成物、ならびにｆｇｆ２アイソフォームの生物学的に活性な混合物の提供
EP3508207A1 (en) Cell preparation and method for producing cell preparation
HK40077940A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40007760B (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40007760A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK1206631B (en) Cells for use in the treatment of brain injury
HK40010333B (en) Method of treating the effects of stroke
HK1196540B (en) Method of treating the effects of stroke
HK1196540A (en) Method of treating the effects of stroke

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170329

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170424

R150 Certificate of patent or registration of utility model

Ref document number: 6134783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250